Progressive encephalopathy with edema, hypsarrhythmia, and optic nerve atrophy (PEHO) syndrome is a rare, apparently autosomal recessive condition in which characteristic dysmorphic features are ...

Besides zorevunersen, STOK is also looking to develop another candidate, STK-002, for the treatment of autosomal dominant optic atrophy. Stoke Therapeutics currently has a Zacks Rank #2 (Buy).